13 results
P
lung disease, li, ipf
I/C
baicalin, no intervention
O
reduced inflammation, decreased apoptosis, protected against progression
P
Patients with odontogenic keratocyst (OKC)
I/C
5-Fluorouracil (5-FU) as an adjunct following surgical intervention, Surgical intervention alone
O
Recurrence rate and nerve paraesthesia
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
Yu X, Xu R, Zhang Z, Yang Y, Deng F
I/C
extra-short implants (≤ 6 mm), longer implants (≥ 8 mm)
O
bone augmentation
P
Li QL, Yao MF, Cao RY, Zhao K, Wang XD
I/C
short dental implants, splinted and nonsplinted prostheses
O
survival rates
P
MAC patients, AC patients
I/C
neoadjuvant treatment regimens comprising chemoradiotherapy (CRT) with fluorouracil (5-FU) or mFOLFOX6, neoadjuvant chemotherapy alone with mFOLFOX6 or mFOLFOXIRI, MAC vs. AC patients
O
pathological complete response (pCR) rate, tumor downstaging rate, 3-year DFS, 3-year locoregional recurrence rate
P
patients with locally advanced rectal cancer (LARC)
I/C
neoadjuvant (chemo) radiotherapy and curative surgery, observation group
O
overall survival (OS), disease-free survival (DFS), toxicity, compliance
P
Individuals participating in blood flow restriction (BFR) training
I/C
BFR training, High-intensity resistance training (HIRT)
O
Muscular strength, hypertrophy, and endurance
P
red yeast rice preparations
I/C
RYR preparations, control treatments
O
adverse health outcomes
P
Orthodontic-surgical treatment patients
I/C
Conventional combined orthodontic-surgical treatment, No treatment or alternative treatments
O
Oral health-related quality of life